Previous 10 | Next 10 |
Gainers: CDLX +20.8% . TWOU +14.6% . DDOG +14.2% . VRAY +9.3% . NBRV +8.4% . More news on: Cardlytics, Inc., 2U, Inc., Datadog, Inc., Stocks on the move, Read more ...
HOUSTON , Nov. 12, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today...
HOUSTON , Nov. 11, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today anno...
HOUSTON , Aug. 15, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indic...
Marker Therapeutics (NASDAQ: MRKR ): Q2 GAAP EPS of -$0.12 beats by $0.01 . More news on: Marker Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
HOUSTON , Aug. 8, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provi...
HOUSTON , Aug. 6, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications...
Marker Therapeutics ( MRKR ) announced that it had achieved positive interim results from its phase 1/2 study using MultiTAA to treat patients with pancreatic cancer. This preliminary data points to the potential for MultiTAA to be used as a front-line therapy with chemotherapy and possibl...
Investors have been anxiously awaiting the results by Marker Therapeutics of their phase 1/2 trial known as TACTOPS, which investigates the use of Multi TAA technology in the treatment of pancreatic cancer. Although Marker has demonstrated the scope and breadth of their technology in liquid ca...
SAN FRANCISCO , July 20, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor in...
News, Short Squeeze, Breakout and More Instantly...
Marker Therapeutics Inc. Company Name:
MRKR Stock Symbol:
NASDAQ Market:
Marker Therapeutics Inc. Website:
Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study Study participant with Non-Hodgkin’s Lymphoma who relapsed within 90 days of anti-CD19 CAR T cell therapy remains in complete response...
Preliminary data from study in patients with lymphoma enrolled at City of Hope National Medical Center was presented at the 11 th Global Summit on Hematologic Malignancies in Whistler, BC, Canada Study participants tolerated initial dose level well and demonstrated durab...